Myocardial infarction remains one of the top killers in the modern world. With the latest advances in stem cell technology, we gained insight towards the therapeutic use of stem cells of different sources (e.g., pluripotent and adipose-derived stem cells, endothelial progenitor cells) and origins (autologous vs. allogeneic). Moreover, discovery of the clinical significance of stem cell-derived exosomes and recent development in nanotechnologies have brought stem cell treatment for cardiovascular diseases to the next level. An in-depth understanding of the molecular mechanisms underlying myocardial infarction including various signaling pathways (e.g., Hippo/YAP, RhoA/ROCK, Nrf2/HO-1, TGF-beta/SMADs) has shed light on the potential therapeutic targets for which further efforts can be made not only to treat the disease and minimize the severity of the subsequent complications, but also to prevent its occurrence. Despite the explosion in knowledge of stem cell treatment for myocardial infarction in recent years, tangible evidence in support of specific therapeutic strategy in clinical setting remains under-discovered.
This Research Topic welcomes recent evidence that can help shaping the current therapeutic strategies for myocardial infarction and its complications as well as improving the long-term outcomes of patients. We aim to create a forum for novel ideas based on recent developments in the therapeutic use of stem cells for myocardial infarction in clinical (e.g., outcomes of relevant trials) or experimental (e.g., stem cell-related cellular and molecular mechanisms). In addition to identifying the missing pieces in the jigsaw puzzle of pathogenesis, high-quality clinical evidence from well-designed studies is welcomed, which is crucial to the tailoring of future treatment strategies to meet individual needs.
We welcome submissions of clinical and basic studies focusing on the exploration of this topic from different perspectives including, but not limited to:
• Recent clinical advances in stem cell-based treatment for myocardial infarction
• Clinical outcomes from randomized controlled trials focusing on stem cell-related therapies for myocardial infarction
• Pooled evidence about the clinical efficacy of stem cell treatments for myocardial infarction including issues of safety and complications
• Experimental studies investigating the efficacy of stem cells for myocardial infarction treatment
• Studies focusing on the mechanisms at cellular or molecular levels that help explaining the efficacy of stem cell treatment for myocardial infarction
• Stem cell manipulation strategies that enhance the therapeutic efficacy of stem cells for myocardial infarction treatment
Myocardial infarction remains one of the top killers in the modern world. With the latest advances in stem cell technology, we gained insight towards the therapeutic use of stem cells of different sources (e.g., pluripotent and adipose-derived stem cells, endothelial progenitor cells) and origins (autologous vs. allogeneic). Moreover, discovery of the clinical significance of stem cell-derived exosomes and recent development in nanotechnologies have brought stem cell treatment for cardiovascular diseases to the next level. An in-depth understanding of the molecular mechanisms underlying myocardial infarction including various signaling pathways (e.g., Hippo/YAP, RhoA/ROCK, Nrf2/HO-1, TGF-beta/SMADs) has shed light on the potential therapeutic targets for which further efforts can be made not only to treat the disease and minimize the severity of the subsequent complications, but also to prevent its occurrence. Despite the explosion in knowledge of stem cell treatment for myocardial infarction in recent years, tangible evidence in support of specific therapeutic strategy in clinical setting remains under-discovered.
This Research Topic welcomes recent evidence that can help shaping the current therapeutic strategies for myocardial infarction and its complications as well as improving the long-term outcomes of patients. We aim to create a forum for novel ideas based on recent developments in the therapeutic use of stem cells for myocardial infarction in clinical (e.g., outcomes of relevant trials) or experimental (e.g., stem cell-related cellular and molecular mechanisms). In addition to identifying the missing pieces in the jigsaw puzzle of pathogenesis, high-quality clinical evidence from well-designed studies is welcomed, which is crucial to the tailoring of future treatment strategies to meet individual needs.
We welcome submissions of clinical and basic studies focusing on the exploration of this topic from different perspectives including, but not limited to:
• Recent clinical advances in stem cell-based treatment for myocardial infarction
• Clinical outcomes from randomized controlled trials focusing on stem cell-related therapies for myocardial infarction
• Pooled evidence about the clinical efficacy of stem cell treatments for myocardial infarction including issues of safety and complications
• Experimental studies investigating the efficacy of stem cells for myocardial infarction treatment
• Studies focusing on the mechanisms at cellular or molecular levels that help explaining the efficacy of stem cell treatment for myocardial infarction
• Stem cell manipulation strategies that enhance the therapeutic efficacy of stem cells for myocardial infarction treatment